Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

- Renowned neuroscience drug developer joins to support strategic development
of long-acting CNS therapeutics –

HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform^™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors.

Read more at globenewswire.com